News
MNMD
5.77
+5.68%
0.31
Psychedelic: MindMed announces dosing in Phase 3 Emerge study
TipRanks · 04/17 15:40
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder
TipRanks · 04/16 17:03
MIND MEDICINE (MINDMED) INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026
Reuters · 04/15 11:00
Weekly Report: what happened at MNMD last week (0407-0411)?
Weekly Report · 04/14 10:44
Weekly Report: what happened at MNMD last week (0331-0404)?
Weekly Report · 04/07 10:44
Weekly Report: what happened at MNMD last week (0324-0328)?
Weekly Report · 03/31 10:53
Psychedelic: Exclusive talk with retreat provider ONE Retreats
TipRanks · 03/27 15:10
MindMed Advances Clinical Programs with Strong Financial Backing
TipRanks · 03/26 22:38
MindMed Appoints New CCO to Drive Commercial Strategy for MM120 Launch
TipRanks · 03/26 22:38
MindMed Issues Inducement Grants to New Employees
TipRanks · 03/26 22:37
Weekly Report: what happened at MNMD last week (0317-0321)?
Weekly Report · 03/24 10:43
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks · 03/21 14:30
Largest borrow rate increases among liquid names
TipRanks · 03/21 12:45
Psychedelic: atai Life Sciences, NRx report quarterly results
TipRanks · 03/20 15:50
MINDMED APPOINTS MATT WILEY AS CHIEF COMMERCIAL OFFICER
Reuters · 03/17 11:00
Weekly Report: what happened at MNMD last week (0310-0314)?
Weekly Report · 03/17 10:52
'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment
Benzinga · 03/12 15:45
Weekly Report: what happened at MNMD last week (0303-0307)?
Weekly Report · 03/10 10:53
Mind Medicine’s (MNMD) Recent Achievements Boosting Stock
TipRanks · 03/08 16:56
Mind Medicine’s Strategic Initiatives and Financial Health Drive Buy Rating
TipRanks · 03/07 16:05
More
Webull provides a variety of real-time MNMD stock news. You can receive the latest news about Mind Medicine through multiple platforms. This information may help you make smarter investment decisions.
About MNMD
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).